16 September 2026 editorial review · Item
Stem-cell-derived islets (zimislecel / VX-880): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: Updated the 1 September NCT04786262 master protocol: VX-880 Phase 1/2/3 plus VX-017 Phase 1/2; 57 estimated participants total; December 2027 primary completion and December 2031 final completion; hepatic portal infusion. Kept VX-880's NEJM n=12 result separate from unreported VX-017 outcomes.
- Registry NCT04786262: RECRUITING; updated 2026-09-01; enrollment 57 (ESTIMATED); primary completion 2027-12-31 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: NEJMoa2506549.